Respicardia is a leading brand in innovative technologies that cater to the needs of individuals with Central Sleep Apnea (CSA). This serious breathing disorder disrupts the normal breathing pattern during sleep, negatively impacting overall health and quality of life. Respicardia's breakthrough solution is the remēdē® System, an implantable device that received FDA approval in October 2017.

The remēdē® System restores a more normal breathing pattern by treating the harmful effects of CSA. With a focus on innovation, Respicardia has been providing effective solutions since its establishment in 2006. The brand was acquired by ZOLL in 2021 and continues to lead the way in addressing the unmet needs of CSA patients.

If you suffer from moderate to severe CSA, consult with your doctor to determine if the remēdē® System is the right solution for you